What the Research Says
Omega-3 fatty acids have demonstrated significant benefits across various health domains, supported by robust evidence from multiple studies. In cardiovascular health, the REDUCE-IT trial (Bhatt et al., 2019) highlighted that a high dose of pure EPA (4g/day) reduced major adverse cardiovascular events by 25%. More recently, Yan et al. (2024) conducted a systematic review and meta-analysis of 15 RCTs, confirming moderate evidence for the reduction of myocardial infarction and cardiovascular death with omega-3 supplementation, though noting an increased risk of atrial fibrillation.
For neurological health, Calderon Martinez et al. (2024) analyzed 14 studies involving 2766 participants, finding that omega-3 fatty acids, including EPA, DHA, and Souvenaid®, slowed cognitive decline in Alzheimer's disease patients as measured by the Clinical Dementia Rating scale. Additionally, a meta-analysis by Liao et al. (2019) confirmed that EPA-predominant formulas significantly alleviate depressive symptoms.
In terms of muscle health, Uchida et al. (2024) reviewed four studies and found that omega-3 supplementation combined with resistance training enhances muscle strength, though not mass. Furthermore, Pradelli et al. (2023) demonstrated that fish oil-based lipid emulsions outperform other intravenous lipid emulsions in improving clinical outcomes, highlighting the broader therapeutic potential of omega-3 fatty acids.
Overall, these findings underscore the diverse and significant benefits of omega-3 fatty acids across cardiovascular, neurological, and musculoskeletal health.




